research Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
Finasteride use is linked to a higher risk of obstructive sleep apnea.
Search
for
Sort by
Research
420-450 / 1000+ resultsresearch Literature ReviewOral Minoxidil for Female Pattern Hair LossTopical Finasteride for Treatment of AGASulfotransferase Activity Predicts Response to Minoxidil
Oral minoxidil helps female hair loss, topical finasteride treats AGA, and sulfotransferase activity predicts minoxidil effectiveness.
research Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
Finasteride use is linked to a higher risk of obstructive sleep apnea.
research Finasteride for Androgenetic Alopecia Is Not Associated with Sexual Dysfunction: A Survey-Based, Single-Centre, Controlled Study
Finasteride does not cause sexual dysfunction in men with hair loss.
research Suicidal behaviors (suicidal ideation, suicide attempt and completed suicide) in patients treated with finasteride for hair loss: Results from the U.S. FDA Adverse Event Reporting System (FAERS) database
research A study of the efficacy of skin needling and platelet rich plasma in the treatment of androgenetic alopecia
research Bio-Based Electrospun Fibers for Wound Healing
Bio-based electrospun fibers improve wound healing but face production and regulatory challenges.
research A preliminary observation: Male pattern hair loss among hospitalized COVID‐19 patients in Spain – A potential clue to the role of androgens in COVID‐19 severity
Male pattern hair loss could hint at androgens affecting COVID-19 severity.
research Androgen sensitivity gateway to COVID ‐19 disease severity
Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.
research Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.
research Regulatory mutations in TBX3 disrupt asymmetric hair pigmentation that underlies Dun camouflage color in horses
Mutations in TBX3 cause horses to have more even hair color instead of Dun camouflage.
research Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti‐androgens a potential treatment for COVID‐19?
Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
research Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
research What does androgenetic alopecia have to do with COVID‐19? An insight into a potential new therapy
Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.
research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
research Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
research 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia
5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
research Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
Spironolactone might help protect against severe lung problems in COVID-19 patients.
research Time of onset and duration of post-COVID-19 acute telogen effluvium
Hair loss from COVID-19 usually starts around 45 days after infection and lasts about 47.5 days.
research Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign
AGA linked to worse COVID-19 outcomes in men.
research Clinical symptoms of hyperandrogenic women diagnosed with COVID‐19
Women with high androgen levels may have more severe COVID-19 symptoms.
research Androgen receptor genetic variant predicts COVID‐19 disease severity: a prospective longitudinal study of hospitalized COVID‐19 male patients
A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
research Combination tofacitinib and oral minoxidil treatment for severe alopecia areata
Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
research Expression of concern: potential risk for developing severe COVID-19 disease among anabolic steroid users
Anabolic steroid users may face higher risk of severe COVID-19.
research IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
research Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial
Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
research Melatonin-Loaded Nanocarriers: New Horizons for Therapeutic Applications
Melatonin-loaded nanocarriers improve melatonin delivery and effectiveness for various medical treatments.
research Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.
Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.
research The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort
The AndroCoV Clinical Scoring is a quick, accurate, and free tool for diagnosing COVID-19.